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Depression and cognitive decline have been associated with changes in circulating cortisol concentrations. Cortisol exerts its functions
through mineralocorticoid (MR) and glucocorticoid (GR) receptors. However, data on the influence of variations in the MR and GR
genes on depressive symptoms and cognitive functioning in older adults are scarce. Therefore, we explored the impact of MR-215G/C,
MR-I180V, GR-ER22/23EK, GR-N363S, and GR-BclI polymorphisms on these end points in the population-based Leiden 85-plus Study.
This prospective study includes 563 participants aged 85 years and older, with a mean follow-up of 4.2 years. In this study, high morning
cortisol levels (per 1 SD cortisol) associated with impairments in global cognitive functioning (p¼ 0.002) at baseline (age 85). These
impairments were mainly attributable to lower attention (p¼ 0.057) and slower processing speed (p¼ 0.014). Similar effects were also
observed during follow-up (age 85–90), where participants with higher cortisol levels (per 1 SD cortisol) had impaired global cognitive
functioning (p¼ 0.003), as well as impairments in attention (p¼ 0.034) and processing speed (p¼ 0.013). Changes in depressive
symptoms were observed for the MR-I180V single-nucleotide polymorphism (SNP), where during follow-up the prevalence of
depressive symptoms was higher in the 180V-allele carriers (p¼ 0.049) compared to noncarriers. Dependent on these polymorphisms,
no differences in overall and in specific domains of cognitive functioning were observed. In conclusion, the MR-I180V SNP has a specific
effect on depressive symptoms, independent from cognitive functioning, and other polymorphisms in the MR and GR genes. In contrast,
these genetic variants in the MR and GR genes do not influence cognitive functioning in old age.
Neuropsychopharmacology (2007) 32, 1295–1301. doi:10.1038/sj.npp.1301260; published online 29 November 2006
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INTRODUCTION
In response to a real or imagined threat the organism reacts
by eliciting a stress response in order to cope with the
stressor. In humans, cortisol is the primary active stress
hormone that mediates counter-responses to stress, aimed
to re-establish homeostasis and coordinate behavioral
adaptations (de Kloet et al, 1998, 2005; Munck et al,
1984). Cortisol exerts its effects through mineralocorticoid
(MR) (NR3C2) and glucocorticoid (GR) (NR3C1) receptors,
which are abundantly co-expressed in the neurons of limbic
structures (Herman, 2003). MRs, which have 10 times
higher affinity for cortisol than GRs, determine the
threshold or sensitivity of the stress system and thus the
onset of the stress response (de Kloet et al, 2005). GRs, on
the other hand, represent the slower mode that promotes
the termination of the stress response (de Kloet et al, 2005).
Balancing these two systems is essential for cell
homeostasis, mental performance, and health.
Various studies have shown that stress-responsiveness is
highly variable among human subjects, and an inadequate
stress response increases vulnerability for disease. Changes
in the stress hormone system have been shown to play a
role in the development of depression (Belanoff et al,
2001b; Holsboer, 2000, 2001). In addition, changes in the
circulating cortisol concentrations have been associated
with impairments in various cognitive domains, includingReceived 22 May 2006; revised and ; accepted 6 October 2006
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attention, perception, and memory (Jameison and Dinan,
2001; Lupien et al, 2005; Newcomer et al, 1999). In terms of
memory, excess cortisol levels have been shown to impair
mainly declarative and not nondeclarative memory (Lupien
et al, 2005).
As MRs and GRs mediate the cortisol signal, variations in
these genes may introduce changes in cortisol signaling
dynamics, and thereby lead to changes in mood and
cognitive function. In the MR gene, the 215G/C and I180V
single-nucleotide polymorphisms (SNPs) have been shown
to change cortisol signaling in vitro (Arai et al, 2003),
whereas in the GR gene the ER22/23EK, N363S, and BclI
SNPs have been shown to change HPA-axis reactivity after a
dexamethasone suppression test or a psychosocial stressor
(Huizenga et al, 1998; van Rossum et al, 2002, 2003). In
addition, the ER22/23EK variant has been associated with
major depression in two studies (van Rossum et al, 2006;
van West et al, 2006). To date, there are no publications that
examine the role of these MR and GR variants in cognitive
functioning and as yet no study has assessed the effects of
variants in the MR gene on mood. Furthermore, a combined
effect of the genetic variants in the MR and GR genes
may have a different effect on depressive symptoms and
cognitive functioning, owing to the interplay between these
genes.
In this study, we examined the influence of cortisol levels
and variants in the MR and GR genes on overall cognitive
functioning, attention, processing speed, immediate and
delayed memory, and on depressive symptoms in old age.
All analyses were performed in the prospective population-
based Leiden 85-plus Study. Since in old age cognitive
decline and depressive symptoms are more prevalent, the
effects of a lifelong exposure to changes in cortisol signaling
owing to polymorphisms should be more easily detectable
on these end points.
SUBJECTS AND METHODS
Subjects
The Leiden 85-plus Study is a population-based prospective
study of inhabitants of the city Leiden, The Netherlands. All
85-year-old inhabitants were invited to participate. There
were no selection criteria related to health or demographic
characteristics. The study population consists of 599
participants, all Caucasians and members of the 1912–
1914 birth cohorts, who were enrolled in the month of their
85th birthday between 1997 and 1999 (Bootsma-van der
Wiel et al, 2002). For the present study DNA was available
for 563 participants. The Medical Ethical Committee of the
Leiden University Medical Center approved the study and
informed consent was obtained from all participants or
their guardian.
Cognitive Function and Depressive Symptoms
Global cognitive functioning was assessed in all participants
with the Mini-Mental State Examination (MMSE) (Folstein
et al, 1975). Participants with a MMSE score 19 points or
higher were subjected to additional tests to measure
attention (Stroop Test) (Klein et al, 1997), processing speed
(Letter Digit Coding Test, LDT) (Houx et al, 2002),
immediate recall memory (Word Learning Test Immediate
Recall, WLTI), delayed recall memory (Word Learning Test
Delayed Recall, WLTD) (Brand and Jolles, 1985) and
depressive symptoms (15-item Geriatric Depression Scale,
GDS-15) (De Craen et al, 2003). The tests assessing specific
domains of cognitive functioning were not administered in
subjects with a MMSE score of 18 points or lower, because
diminished reliability and validity in subjects with severe
cognitive impairment. All participants were visited annually
for re-measurement of cognitive functioning during a mean
follow-up period of 4.2 years. Parallel versions of the tests
were used. Details of cognitive testing are described
elsewhere (Houx et al, 2002).
Cortisol Measurement at Baseline
All blood samples were drawn in the morning before 11AM.
The median time between venipuncture and centrifugation
in our laboratory was 50min (interquartile range: 30–
70min). Nonfasting plasma cortisol levels were determined
by a fluorescence polarization immunoassay using the
Abbott TDx (Abbott Laboratories, Abbott Park, IL) accord-
ing to the manufacturer’s instructions. The within-assay
coefficient of variation was below 5% at different levels.
Possible Confounders
Socio-demographic characteristics, such as sex and level of
education were considered as possible confounders. Educa-
tion was divided into two levels: a lower education level,
including individuals without schooling or with only
primary school education (less than 6 years of schooling),
and those with a higher education level (6 years or more of
schooling). Health related correlates were assessed at
baseline (age 85), and included drug use, obtained from
the pharmacist’s registers, and chronic diseases. Data on the
use of oral corticosteroids were available for all participants.
Chronic diseases included cardiovascular disease, diabetes
mellitus, chronic obstructive pulmonary disease, arthritis,
malignancy, dementia, and Parkinson’s disease. Data were
obtained at baseline from a structured questionnaire and
based on the diagnoses of the general practitioner.
Genotyping
The GR-ER22/23EK polymorphism consists of two SNPs
in codons 22 (rs6189) and 23 (rs6190). The MR-I180V
(rs5522), GR-ER22/23EK, GR-N363S (rs6195), and GR-BclI
(van Rossum et al, 2003) variants were genotyped using an
Assay-by-Design (Applied Biosystems, Foster City, CA),
consisting of PCR primers and TaqMan MGB probes, on an
ABI 7900 HT with real-time PCR (Applied Biosystems). MR-
215G/C (rs2070951) was genotyped using the MassArray
platform according to the protocols of the manufacturer
(Sequenom, San Diego, CA).
Statistical Analysis
Allele and genotype frequencies were calculated and
analyzed for deviation from Hardy–Weinberg equilibrium
using the w2 test. Cortisol levels were converted into z-scores
((individual level"mean level)/SD) in order to normalize
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the data and provide comparable estimates per 1 SD
increase in cortisol level. The cross-sectional (age 85) and
longitudinal (age 85–90) associations between baseline
cortisol levels, cognitive functioning, and depressive symp-
toms were analyzed using a linear regression and a linear
mixed model, respectively. Differences in cortisol levels
dependent on polymorphisms were assessed with a
univariate general linear model. Associations between
genotypes, cognitive functioning, and depressive symptoms
were analyzed using the linear mixed model, estimating the
overall mean difference in cognitive functioning, or
depressive symptoms during follow-up. In multivariate
analyses, the other polymorphisms were added to the model
as independent covariates. The analyses of cognitive
functioning were adjusted for sex and level of education,
and the analyses of depressive symptoms were adjusted for
sex and presence of chronic diseases. All these analyses were
also performed with additional adjustment for cortisol
levels or chronic diseases. The analyses were performed
with SPSS statistical software, version 12.0 (Chicago, IL).
RESULTS
Baseline characteristics of the participants are shown in
Table 1. From the 563 participants, 12 were excluded from
the analyses owing to the use of corticosteroids. Global
cognitive functioning was assessed in all participants using
MMSE. Some 460 (83%) scored 19 points or more on
MMSE, and these subjects performed additional tests,
measuring attention, processing speed, immediate and
delayed recall memory, and depressive symptoms. All 551
subjects were genotyped for the MR-215G/C, MR-I180V,
GR-ER22/23EK, GR-N363S, and GR-BclI polymorphisms.
The genotype distributions and resulting allelic frequencies
of the variants were in agreement with the distribution
predicted by the Hardy–Weinberg equilibrium, and in case
of the GR gene similar to the frequencies observed in other
studies. This is the first study reporting allele frequencies
for the SNPs in the MR gene. Because of the low allele
frequencies of the SNPs (Table 1), the heterozygous and
homozygous minor allele carriers of all the polymorphisms
were combined. However, for the MR-215G/C and
GR-BclI variants, the analyses were also repeated using
all genotypes, as these polymorphisms have higher allele
frequencies.
Global cognitive functioning, attention, processing speed,
memory, and depressive symptoms were assessed at base-
line and re-examined annually during a mean follow-up
period of 4.2 years. During follow-up, there was a significant
increase in depressive symptoms and a decline in cognitive
functioning in all participants (all po0.001). The influence
of plasma cortisol levels on depressive symptoms and
cognitive functioning was assessed at baseline (age 85) and
also during follow-up (age 85–90). The cross-sectional
analysis at age 85 revealed that higher cortisol levels (per
1 SD cortisol) were associated with impairments in overall
cognitive performance. This was observed in the whole
study population (p¼ 0.008), as well as in the restricted
sample (MMSEX19 points) (p¼ 0.002) (Table 2). These
differences were attributable to lower attention (p¼ 0.057)
and slower processing speed (p¼ 0.014) (Table 2). Similar
effects were also observed during follow-up (age 85–90),
where participants with higher cortisol levels (per 1 SD
cortisol) had impaired global cognitive functioning
(p¼ 0.004), attention (p¼ 0.034) and processing speed
(p¼ 0.013) (Table 2). The overall difference in cognitive
functioning and depressive symptoms during follow-up
dependent on cortisol levels (two groups based on median
cortisol level 0.47 mmol/l) is shown in Figure 1.
The influence of MR and GR gene polymorphisms on
plasma cortisol levels is shown in Table 3. Plasma cortisol
levels were associated with the 215G/C variant in the MR
gene, where the C-allele carriers had lower cortisol levels
than noncarriers (p¼ 0.008) (Table 3). In addition, for the
GR-BclI C/G SNP, a trend for an increase in cortisol levels in
G-allele carriers was observed (p¼ 0.084) (Table 3).
Cognitive functioning and the prevalence of depressive
symptoms were also analyzed dependent on the MR and GR
gene polymorphisms. Differences in depressive symptoms
were observed for the MR-I180V SNP, where carriers of the
180V-allele had more depressive symptoms than noncar-
riers (p¼ 0.049) (Table 4, Figure 2). This difference
increased after adjusting for cortisol levels (0.54 points, SE
(0.27), and p¼ 0.043). On the other hand, the analyses with
cognitive functioning dependent on the polymorphisms
revealed no differences, either in overall (Table 4) or in
specific domains of cognitive functioning (data not shown).
The results remained unaltered after the analyses with a
multivariate model, or adjustment for depressive symptoms
and cortisol concentrations (data not shown). The analyses
Table 1 Baseline Characteristics of Study Participants
Number 551
Agea 85 (F)
Female (%) 365 (66%)
Low level of education (%) 356 (65%)
Chronic diseases 391/461
Cortisol (mmol/l)a 0.49 (0.15)
MMSE (points)a 23.9 (6.27)
MMSEX19 points (%) 460 (83%)
Specific domains of cognitiona
Stroop Test (seconds) 82.4 (34.3)
LDT (digits) 17.1 (7.12)
WLTI (pictures) 23.9 (6.00)
WLTD (pictures) 8.65 (2.76)
GDS-15 (points)a 2.32 (2.44)
Polymorphisms (minor allele frequency)
MR-215G/C 0.47
MR-I180V 0.14
GR-ER22/23EK 0.03
GR-N363S 0.05
GR-BclI C/G 0.34
GDS-15, Geriatric Depression Scale 15-item; LDT, Letter Digit Coding Test;
MMSE, Mini-Mental State Examination; WLTI, Word Learning Test Immediate
Recall; WLTD, Word Learning Test Delayed Recall.
aData presented as means with SD.
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using all the MR-215G/C and GR-BclI genotypes did not
provide any extra information.
All the cognitive functioning analyses were repeated with
additional adjustment for chronic diseases, as participants
with higher cortisol levels had a higher prevalence of
chronic diseases at baseline. This adjustment only margin-
ally changed the results (data not shown).
DISCUSSION
In this study, we assessed the impact of cortisol levels and of
variations in the MR and GR genes on cognitive function
and depressive symptoms. The results revealed associations
between high-cortisol levels and cognitive impairment, but
not with depressive symptoms. In contrast, the prevalence
of depressive symptoms was dependent on a variation in the
MR gene, where carriers of the 180V-allele had more
depressive symptoms compared to the noncarriers. This
association remained unchanged after taking into account
the influence of the other polymorphisms in the MR and GR
genes. Variations either in the MR gene or in the GR gene
were not associated with cognitive function.
Similar to observations in other studies, we found an
association between high-cortisol levels and cognitive
impairments. These differences were observed at baseline
(age 85) and also during follow-up period (age 85–90).
Impairments in global cognitive functioning, owing to high
Table 2 Cortisol, Cognitive Functioning and Depressive Symptoms at Baseline (Age 85), and during the Annual Follow-Up (Age 85–90)
Age 85 Age 85–90
Difference per 1SD cortisol Difference per 1SD cortisol
Estimate (SE) p-value Estimate (SE) p-value
All participants (n¼ 551)
MMSE (points) "0.67 (0.25) 0.008 "0.78 (0.27) 0.004
Restricted sample (n¼ 460)a
MMSE (points) "0.40 (0.13) 0.002 "0.37 (0.12) 0.003
Specific domains of cognitive function
Stroop Test (seconds) 3.15 (1.65) 0.057 2.86 (1.34) 0.034
LDT (digits) "0.79 (0.32) 0.014 "0.74 (0.30) 0.013
WLTI (pictures) "0.39 (0.29) 0.187 "0.38 (0.28) 0.186
WLTD (pictures) "0.21 (0.14) 0.129 "0.19 (0.13) 0.160
GDS-15 (points) 0.18 (0.12) 0.146 0.10 (0.13) 0.424
GDS-15, Geriatric Depression Scale 15-item; LDT, Letter Digit Coding Test; MMSE, Mini-Mental State Examination; WLTI, Word Learning Test Immediate Recall;
WLTD, Word Learning Test Delayed Recall.
aRestricted to participants who scored on MMSEX19 points.
p-values in blod o0.05.
Figure 1 Cognitive functioning and depressive symptoms during the mean 4.2-year follow-up period in participants with low (o0.47mmol/l) and high
(40.47mmol/l) cortisol levels. The p-values represent the overall mean differences in cognitive functioning and mood during the follow-up between the two
groups.
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cortisol, were observed in the whole study population, and
also in the restricted sample (MMSEX19 points). In the
restricted sample, the estimates were without exception
smaller, however they had increased significance. This
implies that by excluding severely cognitively impaired
participants we lose some power but increase specificity, as
these participants may have impaired cognition caused by
other factors than high cortisol. From the specific domains
of cognitive functioning, attention, and speed of informa-
tion processing were most affected, whereas for memory
and mood only a modest influence was observed. Intrigu-
ingly, in literature high-cortisol levels have been mainly
associated with memory impairments and depression
(Holsboer, 2000, 2001; Lupien et al, 2005). Most of these
studies have been conducted with exogenous administration
of glucocorticoids or with depressed patients, with higher
cortisol concentrations than observed in this study. There-
fore, it might be that cortisol levels higher than the average
values in older adults are necessary to affect memory
function and depressive symptoms. However, the lack of
associations could also be related to the single cortisol
measurement, or to the tests used in this study. It has been
shown, that not the acute basal cortisol levels, but rather the
change in cortisol levels over time predicts cognitive
impairments in aging (Belanoff et al, 2001a). In addition,
it has been shown that in some cases, cortisol effects on
cognitive performance are very difficult to detect with the
use of standardized, less sensitive cognitive tests. Thus, it is
plausible that the memory tests used in this study are not
sensitive enough to detect cognitive impairments related to
cortisol.
MRs have been implicated in the control of HPA-axis
activity, as they determine the threshold of stress system’s
activation (de Kloet et al, 2005). To date, there is no
information on how polymorphisms in the MR gene
influence these functions. In this study, we found that
plasma cortisol levels were lower in C-allele carries of the
215G/C SNP in the MR gene. As the 215G/C SNP precedes
the start codon of the MR gene (Arai et al, 2003), it could
interfere with the translational start site and thus, lead to a
less efficient translation and change in MR-A and MR-B
balance (Pascual-Le Tallec et al, 2004). However, the
influence of the different MR isoforms on cortisol levels is
not known. From the other MR polymorphisms, we found
that the I180V amino-acid change in the MR gene was
associated with higher prevalence of depressive symptoms.
It has been reasoned that this SNP changes MR’s
transactivational properties (Arai et al, 2003), which might
change stress responsiveness and lead to increased vulner-
ability to develop depressive symptoms. On the other hand,
carriers of the MR-I180V polymorphism did not display any
deficits in overall or in specific domains of cognitive
functioning, which suggests that the polymorphism speci-
fically influences depressive symptoms and not cognitive
functioning. The mechanisms behind cortisol-mediated
effects on cognitive functioning and depressive symptoms
are most probably different, and modulated by different
neuronal pathways and/or contextual conditions (Lupien
et al, 2005).
Table 3 Cortisol Levels (mmol/l) Dependent on the MR and GR
Polymorphisms
Noncarriers Carriers
n Mean (SE) n Mean (SE) p-value
MR-215G/C 135 0.52 (0.01) 376 0.48 (0.01) 0.008
MR-I180V 394 0.49 (0.01) 145 0.48 (0.01) 0.423
GR-ER22/23EK 504 0.49 (0.01) 33 0.49 (0.03) 0.895
GR-N363S 494 0.49 (0.01) 50 0.50 (0.02) 0.491
GR-BclI C/G 234 0.47 (0.01) 288 0.50 (0.01) 0.084
p-values in blod o0.05.
Table 4 Cognitive Functioning and Depressive Symptoms during
the Mean 4.2 year Follow-Up Period Dependent on the MR and
GR Polymorphisms
Noncarriers Carriers
Mean (SE) Mean (SE) p-value
MMSE (points)a
MR-215G/C 25.2 (0.25) 25.6 (0.15) 0.179
MR-I180V 25.5 (0.15) 25.5 (0.23) 0.926
GR-ER22/23EK 25.5 (0.14) 25.8 (0.48) 0.458
GR-N363S 25.5 (0.13) 25.3 (0.43) 0.776
GR-BclI C/G 25.5 (0.19) 25.4 (0.17) 0.809
GDS-15 (points)a
MR-215G/C 3.12 (0.24) 2.98 (0.15) 0.594
MR-I180V 2.90 (0.15) 3.42 (0.23) 0.049
GR-ER22/23EK 3.02 (0.13) 3.53 (0.48) 0.297
GR-N363S 3.04 (0.13) 2.55 (0.41) 0.248
GR-BclI C/G 3.26 (0.19) 2.89 (0.17) 0.133
GDS-15, Geriatric Depression Scale 15-item; MMSE, Mini-Mental State
Examination.
aRestricted to participants who scored on MMSEX19 points.
p-values in blod o0.05.
Figure 2 Prevalence of depressive symptoms in noncarriers and carriers
of the MR-I180V polymorphism during the mean 4.2-year follow-up period.
The p-value represents the overall mean difference in the GDS-15 scores
during follow-up between the two groups. (n) Represents the number of
participants.
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Previously, it has been shown that the GR gene
polymorphisms alter HPA-axis responsiveness and thereby
cortisol sensitivity. The ER22/23EK variation has been
associated with resistance to cortisol (van Rossum et al,
2002), whereas the N363S and BclI polymorphisms were
shown to increase the sensitivity to cortisol (Huizenga et al,
1998; van Rossum et al, 2002, 2003). We reasoned, that the
increased resistance to cortisol attained by the ER22/23EK
variant would protect against the damaging effects of high-
cortisol levels on cognitive decline and depression, whereas
increased cortisol sensitivity would have opposite effects. In
this study, we found no influences of the analyzed
polymorphisms on plasma cortisol levels, or on cognitive
functioning. For depressive symptoms, only a trend for an
influence by the ER22/23EK variant was observed. In
contrast, the 22/23EK-allele carriers tended to have more
depressive symptoms than noncarriers, without any deficits
in cognitive functioning. The lack of a significant difference
in depressive symptoms between the ER22/23EK carriers
and noncarriers in our study may result from the low
number of participants carrying the variant allele. Despite
that, the trend observed in our study, is in accordance with
two recent studies, showing an enrichment of the 22/23EK-
allele in patients with major depression (van Rossum et al,
2006; van West et al, 2006). It could be that in our study the
lack of a distinct influence of the GR gene SNPs on cognitive
functioning and mood is a result of the nonstressful testing
conditions. GRs are activated in response to stress and they
promote the termination of the stress response and
normalization of homeostasis (de Kloet et al, 2005). This
suggests that the effects of the polymorphisms are only seen
in response to stress or challenge, and that testing in basal
conditions does not reveal any differences in cognitive
functioning and depressive symptoms.
The response to stress is modulated by the interplay
between MRs and GRs, and a combined effect of genetic
variants in these genes may have a different effect on
depressive symptoms and cognitive functioning. In this
study, we attempted to take into account the influence of
genetic variability in both the MR and GR genes. However,
the multivariate analysis did not add any extra information.
The cortisol signaling cascade is complex and involves
numerous chaperones, accessory proteins, co-regulators
and interacting transcription factors that permit differentia-
tion between the MR- and GR-mediated actions (De
Bosscher et al, 2003; Pascual-Le Tallec and Lombes, 2005).
For instance, recently it was found that increase in
recurrence of depressive episodes is associated with a
variant in a gene (FKBP5) that regulates GR activity (Binder
et al, 2004). Therefore, not only genes directly involved in
stress-induced signaling pathways, but genes regulating
their activity also appear to be involved in the development
of these disorders, and their actions should be analyzed in
more detail.
Strengths of the present study include the population-
based sample of the oldest old with high incidence of
depression and cognitive decline, and the annual repeated
assessment of depressive symptoms and various cognitive
domains. A major limitation of the study is the one time
cortisol measurement. Cortisol is secreted diurnally, and the
single measurement of cortisol over an entire day of the
circadian cortisol secretion, considerably weakens the value
of this measure. Cortisol levels measured only once could be
confounded by acute effects, and not reflect the basal
concentration. It has been shown, that cortisol is relatively
stable from day to day but it is not indisputably stable
across the years. Therefore, the results on the predictability
of baseline cortisol levels on cognitive decline over the years
should be interpreted with care. Another limitation of the
study is the lack of data on HPA-axis reactivity, or on other
parameters that reflect the stress system’s activity.
In conclusion, this is the first study looking into the
influence of polymorphisms in the MR and GR genes on
mood and cognitive functioning in older adults. We found
an association between high baseline cortisol levels and
impairments in cognitive functioning during follow-up.
However, no differences in cognitive functioning were
observed dependent on the polymorphisms in the MR and
GR genes. On the other hand, the I180V variant in the MR
gene influenced the prevalence of depressive symptoms,
independently from cognitive functioning.
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